Interest Paid, Excluding Capitalized Interest, Operating Activities of ELITE PHARMACEUTICALS INC /NV/ from 31 Mar 2016 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Summary
ELITE PHARMACEUTICALS INC /NV/ quarterly and annual Interest Paid, Excluding Capitalized Interest, Operating Activities in USD history and change rate from 31 Mar 2016 to 30 Jun 2025.
  • ELITE PHARMACEUTICALS INC /NV/ Interest Paid, Excluding Capitalized Interest, Operating Activities for the quarter ending 30 Jun 2025 was $158,926, a 29% decline year-over-year.
  • ELITE PHARMACEUTICALS INC /NV/ annual Interest Paid, Excluding Capitalized Interest, Operating Activities for 2024 was $672,409, a 463% increase from 2023.
  • ELITE PHARMACEUTICALS INC /NV/ annual Interest Paid, Excluding Capitalized Interest, Operating Activities for 2023 was $119,412, a 89% decline from 2022.
  • ELITE PHARMACEUTICALS INC /NV/ annual Interest Paid, Excluding Capitalized Interest, Operating Activities for 2022 was $1,098,537, a 518% increase from 2021.
Source SEC data
View on sec.gov
Interest Paid, Excluding Capitalized Interest, Operating Activities, Quarterly (USD)
Interest Paid, Excluding Capitalized Interest, Operating Activities, YoY Quarterly Change (%)
Interest Paid, Excluding Capitalized Interest, Operating Activities, Annual (USD)
Interest Paid, Excluding Capitalized Interest, Operating Activities, YoY Annual Change (%)

ELITE PHARMACEUTICALS INC /NV/ Quarterly Interest Paid, Excluding Capitalized Interest, Operating Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $158,926 -$64,044 -29% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2026 Q1
Q2 2024 $222,970 +$103,558 +87% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2026 Q1
Q2 2023 $119,412 -$97,375 -45% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2025 Q1
Q2 2022 $216,787 +$202,744 +1444% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2024 Q1
Q2 2021 $14,043 -$10,299 -42% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2023 Q1
Q2 2020 $24,342 +$4,105 +20% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2022 Q1
Q2 2019 $20,237 -$3,807 -16% 01 Apr 2019 30 Jun 2019 10-Q 14 Aug 2020 2021 Q1
Q2 2018 $24,044 +$4,356 +22% 01 Apr 2018 30 Jun 2018 10-Q 09 Aug 2019 2020 Q1
Q2 2017 $19,688 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2019 Q1

ELITE PHARMACEUTICALS INC /NV/ Annual Interest Paid, Excluding Capitalized Interest, Operating Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $672,409 +$552,997 +463% 01 Apr 2024 31 Mar 2025 10-K 30 Jun 2025 2025 FY
2023 $119,412 -$979,125 -89% 01 Apr 2023 31 Mar 2024 10-K 30 Jun 2025 2025 FY
2022 $1,098,537 +$920,901 +518% 01 Apr 2022 31 Mar 2023 10-K 01 Jul 2024 2024 FY
2021 $177,636 +$1,457 +0.83% 01 Apr 2021 31 Mar 2022 10-K 29 Jun 2023 2023 FY
2020 $176,179 -$64,606 -27% 01 Apr 2020 31 Mar 2021 10-K 29 Jun 2022 2022 FY
2019 $240,785 +$14,330 +6.3% 01 Apr 2019 31 Mar 2020 10-K 14 Jun 2021 2021 FY
2018 $226,455 +$91,309 +68% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020 2020 FY
2017 $135,146 -$7,205 -5.1% 01 Apr 2017 31 Mar 2018 10-K 21 Jun 2019 2019 FY
2016 $142,351 -$73,527 -34% 01 Apr 2016 31 Mar 2017 10-K 14 Jun 2018 2018 FY
2015 $215,878 01 Apr 2015 31 Mar 2016 10-K 14 Jun 2018 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.